Organon Acquires U.S. Rights to TOFIDENCE (tocilizumab-bavi) from Biogen
April 1, 2025
Organon has acquired regulatory and commercial rights in the United States for TOFIDENCE (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. The deal includes an upfront payment to Biogen and Organon will assume tiered royalty and milestone obligations while Bio‑Thera Solutions will retain manufacturing rights for the U.S. market.
- Buyers
- Organon
- Targets
- TOFIDENCE (tocilizumab-bavi)
- Sellers
- Biogen Inc.
- Industry
- Pharmaceuticals
- Location
- United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.